Amylyx Pharmaceuticals
MA - CambridgePharmaceutical
Focus: Amylyx is a neurology-focused specialty pharma company built on a single marketed product (RELYVRIO) combining two existing drugs for rare metabolic disorders. The company generates 100% of revenue from RELYVRIO, indicating a high-risk, single-asset dependency model.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Open Jobs
9+9 this month
Growing — net +9 jobs in 30d
14 jobs added vs 5 removed. Steady team buildout.
Should You Work at Amylyx Pharmaceuticals?
AI assessmentHigh-reward but high-risk specialty biotech play suitable only for candidates comfortable betting on rare disease commercialization and pipeline execution under financial opacity.
Why Work Here
- Commercializing a $198M Part D revenue-generating drug with peak lifecycle status and LOE protection until 2040 — rare opportunity for stability in rare disease
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$198M Part DStable
Peak
Help build intelligence for Amylyx Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.